ArticleCancers2020

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.

Kuan-Yin Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.